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points were similar: median PFS (2.3 v 2.3 months, hazard ratio: 1.004 
[0.841-1.199]), response rate (4.4% v 5.5%), stable disease (36.0% v 
39.6%), median overall survival (6.7 v 7.2 months, hazard ratio: 0.973 
[0.805-1.176]). Clinical beneﬁt was a composite endpoint based on PS, 
weight, PPI, analgesic consumption, dyspnoea and cough; the primary 
endpoint of clinical beneﬁt analysis was the rate of clinical beneﬁt 
responders, deﬁned as those patients who demonstrated improvement 
in at least one of these parameters, without deterioration in any other 
parameter, and conﬁrmed once at least three weeks later. No signiﬁcant 
difference was observed in the rate of clinical beneﬁt between the vin-
ﬂunine arm (31 responders, 13.1%, 95% CI 9.1-18.0) and the docetaxel 
arm (39 responders, 15.5%, 95% CI 11.3-20.6: c2, p=0.4389). 
Conclusion: Vinﬂunine 320 mg/m2 every 3 weeks was found to be 
similar in terms of efﬁcacy to docetaxel 75 mg/m2 every 3 weeks in 
patients previously treated with a platinum-containing regimen for 
advanced NSCLC patients. Clinical beneﬁt was also comparable for the 
two study treatments. Low, manageable but different toxicity proﬁles 
were observed in either arm allowing a good median relative dose in-
tensity > 98%. Therefore, vinﬂunine offers a new and useful alternative 
for patients suffering from advanced NSCLC in second line setting.
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Background: Platinum-based chemotherapy doublets represent the 
standard ﬁrst-line treatment of patients with locally advanced or 
metastatic non-small cell lung cancer (NSCLC), although toxicity is 
common. Several randomized trials trying to assess whether non-plati-
num combinations were as effective as platinum-based ones yielded 
conﬂicting results. Moreover, another not completely solved question 
is whether triplet regimens could be more effective than chemotherapy 
doublets. This 2 x 2 factorial trial aimed at answering both questions: 
(1) the role of replacing cisplatin (P) with vinorelbine (N), (2) the role 
of adding a third agent, ifosfamide (I), in a chemotherapy doublet with 
gemcitabine (G). Primary endpoint was overall survival (OS). Second-
ary endpoints were response rate (RR), progression-free survival (PFS) 
and toxicity.
Methods: Patients with stage IIIB or IV NSCLC were randomly as-
signed to one of four ﬁrst-line regimens: gemcitabine 1250 mg/m2 on 
days 1, 8 plus cisplatin 80 mg/m2 on day 1 (GP); gemcitabine 1250 
mg/m2 on days 1, 8 plus vinorelbine 25 mg/m2 on days 1, 8 (GN); gem-
citabine 1000 mg/m2 on days 1, 8 plus ifosfamide 2 g/m2 on day 1 plus 
cisplatin 80 mg/m2 on day 1 (GIP); gemcitabine 1000 mg/m2 on days 1, 
8 plus vinorelbine 25 mg/m2 on days 1, 8 plus ifosfamide 3 g/m2 on day 
1 (GIN). Treatments were repeated every 3 weeks for a maximum of 6 
cycles. Considering the 2 x 2 trial design, two comparisons have been 
performed: (1) N-containing vs P-containing regimens [GN and GIN vs 
GP and GIP] and (2) I-triplets vs I-non containing doublets [GIN and 
GIP vs GN and GP]. 
Results: From 10/2001 to 07/2006, a total of 433 patients were 
randomized. The patients characteristics were as follows: 72% males, 
with median age of 63 years (range of 29-79), 40% adenocarcinomas, 
71% stage IV and 53% with ECOG performance status of 0. About 
the comparison (1), RR was 25.6 vs 36.3% (p = 0.032), PFS 5.0 vs 6.5 
months (p = 0.239) and OS 11.1 vs 9.8 months [Hazard Ratio (HR) = 
1.04; 95% C.I.: 0.82-1.33; p = 0.719] for N-containing vs P-contain-
ing regimens, respectively. About the comparison (2), RR was 29.1 vs 
32.8% (p = 0.471), PFS 6.5 vs 5.5 months (p = 0.519) and OS 10.8 vs 
9.8 months (HR = 0.95; 95% C.I.: 0.74-1.21; p = 0.705) for I-triplets vs 
I-non containing doublets, respectively. Grade 3-4 anaemia, leucopenia 
and thrombocytopenia were signiﬁcantly more frequent in P-containing 
regimens; only grade 3-4 leucopenia was more common in I-triplets. 
Concerning non-haematological toxicity, only grade 3-4 nausea-vom-
iting was signiﬁcantly increased in P-containing regimens; no other 
statistically signiﬁcant difference in toxicity was observed. 
Conclusions: Results of this unplanned preliminary analysis indicate 
that replacing P with N or the addiction of I to a chemotherapy doublet 
regimen did not improve OS in the treatment of stage IIIB-IV NSCLC 
patients. However, P-containing regimens showed a statistically signiﬁ-
cant advantage in RR over P-free chemotherapy. 
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Background: Chemotherapeutic response rate would be different by 
the ethnic background. This is a randomized prospective trial of three 
cisplatin-based chemotherapeutic regimens in Korean patients with 
advanced non-small-cell lung cancer.
Methods: A total of 333 patients with advanced non-small cell lung 
cancer were randomly assigned to one of the three regimens of 3-
weekly cycle: cisplatin of 60 mg/m2 on day 1 with docetaxel of 75mg/
m2 (DP) or paclitaxel of 130 mg/m2 (TP) on day 1, or gemcitabine of 
1200mg/m2 on day 1 and 8 (GP). After 2~3 cycles of chemotherapy, 
non-responding patients were crossly assigned to the second-line 
monotherapy of either docetaxel or gemcitabine.
Results: There was no signiﬁcant difference in sex, stage, and perfor-
mance status (PS) score, number of cycles and delivered dose inten-
sity between the 3 groups. Three fourths of the patients had stage IV 
disease and one fourth showed ECOG PS score of 2. Mean cycle of 
the ﬁrst-line chemotherapy was 3.4, and the relative dose intensity was 
97%. The overall response rate was 41.8%, with a median survival of 
328 days (95% CI: 271~385) and median progression free survival of 
139 days (95% CI: 111~167 days). The response rate and progression 
free survival did not differ among the 3 groups. The ﬁrst-line treatment 
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with GP regimen was associated with a signiﬁcantly lower incidence 
of grade 3, 4 neutropenia than DP or TP (8.2% vs. 22.8% or 15.6 %, 
respectively: p=0.022), but the incidence of grade 3, 4 thromobocyto-
penia was higher (7.3% vs. 1.8% or 0%, respectively: p<0.0001). In pa-
tients older than 60 years, median time to progression was signiﬁcantly 
prolonged (171 days, 95% CI: 149~193) than the younger patients (97 
days, 95% CI: 70~24) (p<0.0003). However, overall survival was not 
different between the two age groups. Multivariate Cox regression 
analysis showed that the independent predictors of overall survival 
were stage and ECOG performance status.
Conclusions: There were no differences in survival advantages among 
the three regimens in the treatment of Korean patients with advanced 
non-small-cell lung cancer. 
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Objective: Non-small cell lung cancer (NSCLC) with pulmonary 
metastasis in the primary lobe (PM+) is classiﬁed as pathological stage 
IIIB. Although stage IIIB PM+ indicates a poor prognosis, this stage 
includes various subgroups with heterogeneous clinical outcome. Three 
possible mechanisms of intrapulmonary metastasis have been postulat-
ed: 1) via lymphatic vessel route, 2) blood vessel route, 3) airway route. 
Two of these metastatic mechanisms, the lymphatic and hematogenous 
spread by cancer cells, increase the chance of remote organ metastasis. 
Circulating tumor cells have a greater possibility of implanting distally 
and several investigators have actually described a positive correla-
tion between vessel invasion and distant metastasis or recurrence. On 
the other hand, a process in which tumor cells shed at the primary site 
implant and form a separate tumor via the airway route, namely aerog-
enous spread, is sometimes observed in primary lung cancer. Therefore, 
NSCLC with intrapulmonary metastasis via the aerogenous route might 
be regarded as local disease because of the absence of systemic dis-
semination via lymph vessels and blood vessels.
The objective of this study was to extract a subgroup of stage IIIB PM+ 
NSCLC patients with a better prognosis and assess their biological 
characteristics and metastatic mechanisms.
Methods: We reviewed 122 case of surgically resected stage IIIB PM+ 
NSCLC among the 1912 consecutive NSCLC patients who underwent 
complete surgical resection at our hospital between July 1992 and 
December 2004 and extracted a subgroup with a favorable outcome 
by univariate analysis of clinicopathological factors. The 15 cases 
without lymph-node metastasis and vessel invasion (PM+/N-/VI-) were 
extracted as the most favorable group. We assessed the clinicopatho-
logical features of the PM+/N-/VI- group in comparison with the other 
stage IIIB PM+ patients. 
Results: The survival rate of the PM+/N-/VI- group was signiﬁcantly 
better than in the other stage IIIB PM+ group (p=0.0042). Five-year 
disease-speciﬁc survival rates of the PM+/N-/VI- group and the other 
stage IIIB PM+ group were 91.7% and 39.5%, respectively. Microscop-
ic characteristics of the metastatic lesions suggesting that the cancer 
cells had implanted via the aerogenous route were seen in 86.7% of the 
PM+/N-/VI- group, as opposed to only 9.4% of the other PM+ cases 
(We considered that cancer cells with lepidic growth and no destruction 
of bronchovascular bundles and alveolar septa in the metastatic foci 
might have resulted from aerogenous spread whereas cancer cells that 
had formed solid nests and destroyed neighboring alveolar septa as they 
grew had not resulted from aerogenous metastasis). The histological 
type of primary tumors in the PM+/N-/VI- group was adenocarcinoma 
in every cases (p=0.021). Four were the mucinous BAC dominant sub-
type and 11 were the papillary dominant subtype. Furthermore, all 4 pa-
tients in the PM+/N-/VI- group who experienced a recurrence relapsed 
with intrapulmonary metastasis, not distant organ metastasis.
Conclusions: Stage IIIB PM+ cases via the airway route were enriched 
in the PM+/N-/VI- group and had extremely good survival rate. This 
group should be recognized as local disease and if relapse occurs in the 
remnant lobe, it may be possible of to achieve a cure by local therapy.
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Background: Early lung adenocarcinoma (ELA) can be frequently 
detected with thoracic computed tomography. The optimal management 
for those lesions still remains to be a matter of debate. Objectives: To 
clarify preoperative prognostic factors among clinical IA adenocarci-
noma of the lung. 
Patients and Methods: Between January of 2000 and December of 
2005, surgical resection was performed on 2175 lung cancer patients at 
National Cancer Center Hospital, Tokyo. A retrospective study was per-
formed on 444 lung cancers which met the following eligibility criteria: 
1) clinical IA disease, 2) histologically diagnosed adenocarcinoma, 
3) lobectomy or pneumonectomy performed, 4) thoracic thin-section 
CT available. We reviewed all of the above patients for preoperative 
clinico-radiological prognostic factors. Evaluated radiological factors 
were maximum tumor dimension, the presence of ground-glass opacity, 
the size of consolidation, the nature of consolidation (cloudy vs solid), 
pleural tail, and the presence of air bronchogram. Clinical factors were 
evaluated as to preoperative carcinoembryonic antigen (CEA) titer, 
gender and age. Uni- and multi-variate analyses were performed to 
detect predictors of pathological ELA, which was deﬁned as lung ad-
enocarcinoma without nodal disease, lymphatic invasion, nor vascular 
invasion.
